Sharp Aims to Halt Niemann-Pick Disease at Its Cellular Root

PITTSBURGH, PA – May 28, 2026 – Biotechnology firm Sharp Therapeutics today announced encouraging preclinical data for a novel therapeutic approach to Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. The findings, presented at a major scientific conference, suggest the company’s small-molecule drug candidate may be able to address the underlying cellular cause of the disease, a significant step beyond recently approved treatments that primarily manage its devastating symptoms.

Using its proprietary Disco™ discovery platform, the company has identified a chemical series that demonstrated a powerful, multi-pronged effect in laboratory studies on cells derived from NPC patients. This development not only offers a new avenue of hope for a community grappling with a brutal disease but also serves as a key validation for Sharp's technology as it expands its pipeline into challenging hereditary conditions.

A Multi-Pronged Cellular Strategy

The data, unveiled at the 2026 Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research, details a potential breakthrough in how the disease could be treated. In NPC, a genetic mutation—most often in the NPC1 gene—prevents cells from properly transporting cholesterol out of their internal recycling centers, the lysosomes. This leads to a toxic buildup of cholesterol and other lipids, causing widespread cellular dysfunction and, ultimately, catastrophic damage to the brain, liver, and spleen.

Sharp's lead compounds were shown to directly counteract this hallmark pathology. In primary fibroblast cells from NPC patients with various genetic mutations, the molecules significantly reduced the accumulation of intracellular cholesterol at what scientists call “sub-micromolar concentrations.” This indicates high potency, a crucial feature suggesting that a relatively low dose could be effective, potentially minimizing side effects.

Crucially, the benefits did not stop there. The research also showed the compounds prompted an increase in lysosomal exocytosis—a cellular process for expelling waste—and reversed the hyperactivation of the mTOR signaling pathway. The mTOR pathway is a master regulator of cell growth and metabolism, and its dysregulation is a known contributor to the neurodegeneration seen in NPC and other lysosomal storage disorders. By targeting these three distinct but interconnected aspects of the disease—cholesterol buildup, waste clearance, and cellular signaling—Sharp’s approach aims to restore cellular health from the inside out.

“Our lead chemical series significantly reduced the cholesterol accumulation central to NPC pathology, while additional lysosomal exocytosis and mTOR signaling data support a potentially differentiated approach targeting key aspects of the underlying disease biology,” said Scott Sneddon, Ph.D., J.D., Chief Executive Officer of Sharp Therapeutics, in a statement. The company is now focused on advancing an orally available, CNS-penetrant candidate, designed to be taken as a pill and capable of crossing the blood-brain barrier to treat the disease's severe neurological effects.

The Human Cost of Niemann-Pick Type C

For families affected by NPC, the promise of a disease-modifying therapy cannot come soon enough. Affecting an estimated 1 in 100,000 live births, NPC is a relentlessly progressive disorder. Its onset and symptoms vary widely, often leading to a painful “diagnostic odyssey” that can take years. Some children present with liver and lung disease as infants, while others appear healthy until clumsiness, learning difficulties, or psychiatric issues emerge in childhood or even adulthood.

The progression is marked by a tragic decline. Neurological symptoms include a characteristic inability to move the eyes vertically, followed by loss of muscle control (ataxia), difficulty speaking (dysarthria), and trouble swallowing (dysphagia). Many patients develop seizures and a unique form of muscle collapse triggered by emotion, known as cataplexy. With an average lifespan of around 13 years, the disease extracts a devastating toll on patients and their caregivers.

“It’s a race against time from the moment of diagnosis,” explained one researcher familiar with the disease. “You’re watching a progressive erosion of a child’s abilities. Finding a treatment that could actually halt or reverse that process at the source would be a paradigm shift.”

A Crowded Field with Unmet Needs

The therapeutic landscape for NPC has recently seen important progress. In late 2024, the FDA approved two new drugs, Miplyffa (arimoclomol) and Aqneursa (N-acetyl-L-leucine), to treat the neurological symptoms of the disease. These approvals, along with the long-available Miglustat in Europe and other regions, provide valuable tools for managing the condition. However, they are not cures, and a significant need remains for treatments that can fundamentally alter the disease course across both neurological and visceral (organ-related) manifestations.

This is where Sharp Therapeutics hopes to differentiate itself. While other pipeline candidates, such as Trappsol Cyclo, aim to pull cholesterol out of cells, Sharp’s strategy is to fix the internal machinery. The goal of creating an oral, CNS-penetrant small molecule is particularly ambitious. Such a drug would offer the convenience of a pill while ensuring the therapy reaches the brain, the primary site of irreversible damage in NPC.

By targeting the root cause, a therapy like the one Sharp is developing could potentially offer benefits beyond what current symptom-management drugs can achieve, raising the prospect of not just slowing the disease, but stabilizing or even improving function.

Platform Validation and a High-Risk Bet

This announcement is also a significant moment for Sharp Therapeutics as a preclinical-stage company. The positive NPC data provides critical validation for its Disco™ discovery platform, which combines high-throughput screening, advanced physics, and AI-driven analytics to find small molecules capable of correcting defects in mutated proteins. The platform is also being applied to other genetic disorders, including Gaucher Disease and Familial Frontotemporal Dementia.

Success in a complex disease like NPC demonstrates the platform's potential to generate promising candidates for conditions that have long been considered intractable. However, the path forward is fraught with risk. Like most preclinical biotechs, Sharp is a pre-revenue company that relies heavily on its ability to raise capital to fund its costly research and development. Public filings show a company burning through cash, a common but precarious position in this industry.

Despite the financial risks, the strength of the science has attracted investor support, with key partners committing to funding the company through its next critical milestones. Sharp is now continuing medicinal chemistry efforts to optimize its lead compounds and plans to conduct further in vitro and in vivo studies to select a final clinical candidate. If all goes well, the company hopes to begin the formal IND-enabling studies required to enter human trials, marking the next major step on the long journey from a laboratory finding to a potential medicine.